Scientific Overview

Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease-causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.

Lawrence Blatt, Ph.D., MBA

Chief Executive Officer

• Global Infectious Diseases Therapeutic Area Head – Janssen
• Co-Founder, Chief Executive Officer – Alios BioPharma
• Chief Scientific Officer – InterMune
• Senior Vice President, Research – Ribozyme/SIRNA
• Senior Director, Interferon Research – Amgen

Leo Beigelman, Ph.D.

President

• Global Head Discovery Infectious Diseases – Janssen
• Co-Founder, CSO – Alios BioPharma
• Director Chemistry – Ribozyme/SIRNA, InterMune

Julian Symons, D.Phil.

Executive Vice President
Chief Scientific Officer

• Vice President, Disease Area R&D Leader, Respiratory Infections – Janssen
• Senior Director, Product Development – Alios BioPharma
• Virology Director – Roche

Lucinda Quan, JD

Executive Vice President
General Counsel
Head of Business Development & Operations

• Executive. Director, Head Transactionalist, West Coast Hub for Business Development & Licensing – Merck
• Vice President, Head of Legal Affairs – Alios BioPharma
• Vice President, Legal Affairs & Associate General Counsel – InterMune

Sushmita Chanda, Ph.D., DABT

Executive Vice President
Preclinical Development

• Vice President, Global Head of Preclinical Development, Infectious Diseases – Janssen
• Vice President, Head of Preclinical Development – Alios BioPharma
• Senior Director, Nonclinical Safety – Roche

John Fry

Executive Vice President
Clinical Development

• Vice President, Global Head of Early Development, Infectious Diseases – Janssen
• Vice President, Head of Clinical Development – Alios BioPharma
• Director, Clinical Research, Gilead Sciences

Brian Dowd

Executive Vice President
Controller

• Senior Vice President, Finance & Controller – Second Genome
• Vice President, Controller – Janssen
• Vice President, Controller – Alios BioPharma
• Vice President, Corporate Controller – Codexis

David B. Smith, Ph.D.

Vice President
Head of Chemical Operations

• Vice President, Global Disease Area R&D Leader, Hepatology – Janssen
• Senior Director, Product Development – Alios BioPharma
• Principal Research Scientist – Roche

Pierre Raboisson, Pharmacist D., Ph.D

Vice President
Head of Small Molecule Medicinal Chemistry
Head of Belgium Site (Leuven)

• Vice President, Global Head of Medicinal Chemistry – Infectious Disease – Janssen
• Vice President, Head of Infectious Diseases Discovery EU – Janssen
• Vice President, Head of Medicinal Chemistry Europe – Janssen